Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
The FDA's first new sunscreen approval in over two decades is now on store shelves. Neutrogena has launched products containing bemotrizinol (BEMT), a UV-blocking ingredient long available in Europe that offers superior UVA and UVB protection with low skin absorption. CeraVe and La Roche-Posay are expected to follow soon.
After more than 20 years without a new approved sunscreen ingredient, the FDA gave bemotrizinol (BEMT) the green light in June 2026 — and it's already hitting retail shelves. Neutrogena was first out of the gate, launching two BEMT-containing sunscreens (SPF 60 and SPF 70), with CeraVe and La Roche-Posay expected to follow. BEMT had already been approved in Europe for 25 years, and the FDA's review confirmed it protects against both UVA and UVB rays, is minimally absorbed through the skin, and rarely causes irritation.
Dermatologists are encouraged — not just about the protection, but about the feel. Experts say BEMT's superior cosmetic texture could encourage more consistent sunscreen use, a longstanding challenge in skin cancer prevention. Prices range from $16–$20, though experts hope the media attention will boost sunscreen awareness more broadly.
By the Numbers:
Why it matters: Better UVA protection and improved wearability could meaningfully increase sunscreen adherence — a key factor in reducing skin cancer risk and premature aging at the population level.
